Dr Reddy's Laboratories Revenue 2010-2024 | RDY
Dr Reddy's Laboratories annual/quarterly revenue history and growth rate from 2010 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Dr Reddy's Laboratories revenue for the quarter ending September 30, 2024 was $0.954B, a 15.19% increase year-over-year.
- Dr Reddy's Laboratories revenue for the twelve months ending September 30, 2024 was $3.576B, a 11.99% increase year-over-year.
- Dr Reddy's Laboratories annual revenue for 2024 was $3.35B, a 11.97% increase from 2023.
- Dr Reddy's Laboratories annual revenue for 2023 was $2.992B, a 5.87% increase from 2022.
- Dr Reddy's Laboratories annual revenue for 2022 was $2.826B, a 8.94% increase from 2021.
Dr Reddy's Laboratories Annual Revenue
(Millions of US $) |
| 2024 |
$3,350 |
| 2023 |
$2,992 |
| 2022 |
$2,826 |
| 2021 |
$2,594 |
| 2020 |
$2,316 |
| 2019 |
$2,225 |
| 2018 |
$2,181 |
| 2017 |
$2,171 |
| 2016 |
$2,335 |
| 2015 |
$2,378 |
| 2014 |
$2,203 |
| 2013 |
$2,133 |
| 2012 |
$1,901 |
| 2011 |
$1,677 |
| 2010 |
$1,563 |
| 2009 |
$ |
Dr Reddy's Laboratories Quarterly Revenue
(Millions of US $) |
| 2024-09-30 |
$954 |
| 2024-06-30 |
$921 |
| 2024-03-31 |
$835 |
| 2023-12-31 |
$866 |
| 2023-09-30 |
$828 |
| 2023-06-30 |
$821 |
| 2023-03-31 |
$718 |
| 2022-12-31 |
$826 |
| 2022-09-30 |
$788 |
| 2022-06-30 |
$660 |
| 2022-03-31 |
$671 |
| 2021-12-31 |
$715 |
| 2021-09-30 |
$778 |
| 2021-06-30 |
$662 |
| 2021-03-31 |
$673 |
| 2020-12-31 |
$675 |
| 2020-09-30 |
$661 |
| 2020-06-30 |
$585 |
| 2020-03-31 |
$458 |
| 2019-12-31 |
$618 |
| 2019-09-30 |
$682 |
| 2019-06-30 |
$558 |
| 2019-03-31 |
$604 |
| 2018-12-31 |
$535 |
| 2018-09-30 |
$543 |
| 2018-06-30 |
$543 |
| 2018-03-31 |
$525 |
| 2017-12-31 |
$590 |
| 2017-09-30 |
$553 |
| 2017-06-30 |
$513 |
| 2017-03-31 |
$608 |
| 2016-12-31 |
$546 |
| 2016-09-30 |
$538 |
| 2016-06-30 |
$479 |
| 2016-03-31 |
$527 |
| 2015-12-31 |
$603 |
| 2015-09-30 |
$614 |
| 2015-06-30 |
$591 |
| 2015-03-31 |
$621 |
| 2014-12-31 |
$610 |
| 2014-09-30 |
$579 |
| 2014-06-30 |
$586 |
| 2014-03-31 |
$580 |
| 2013-12-31 |
$571 |
| 2013-09-30 |
$537 |
| 2013-06-30 |
$478 |
| 2013-03-31 |
$613 |
| 2012-12-31 |
$522 |
| 2012-09-30 |
$544 |
| 2012-06-30 |
$457 |
| 2012-03-31 |
$522 |
| 2011-12-31 |
$522 |
| 2011-09-30 |
$462 |
| 2011-06-30 |
$444 |
| 2011-03-31 |
$453 |
| 2010-12-31 |
$424 |
| 2010-09-30 |
$420 |
| 2010-06-30 |
$363 |
| 2010-03-31 |
$365 |
| 2009-12-31 |
$373 |
| 2009-09-30 |
$382 |
| 2009-06-30 |
$381 |
| 2009-03-31 |
$390 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$11.803B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
